GRAIL Inc Dossier - Source-backed chat

GRAIL Inc

GRALNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)2.50

Intrinsic Value $45.83median of 2 methodsbased on filings through 30 Jun 2026

Market Price $132.56Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 65% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-65%)

Data confidence Sign in to view data confidence

Market Cap $5.9B

Enterprise Value $5.9B

Shares Outstanding 43.6M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

GRAIL, Inc. (NASDAQ: GRAL) is a pioneer in the multi-cancer early detection (MCED) market with its flagship Galleri test. While the company continues to demonstrate robust commercial momentum—evidenced by a 28% YoY revenue increase to $40.8 million and a 50% increase in test volumes in Q1 2026—it faces significant near-term headwinds. The landmark NHS-Galleri trial failed to meet its primary endpoint of a statistically significant reduction in Stage III-IV cancers, which has triggered multiple securities class action lawsuits and introduced substantial uncertainty regarding broad regulatory and reimbursement timelines. Although the transition to Dr. Joshua Ofman as CEO on June 1, 2026, provides leadership stability and the company maintains a strong cash runway of $823.1 million, the stock remains highly volatile. A Hold rating is recommended until there is greater clarity on the FDA PMA review and long-term reimbursement pathways.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$60.00

Mean target$72.38

High · most bullish analyst$88.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$60.0020%

The FDA issues a non-approvable letter or requests additional large-scale clinical trials, significantly delaying commercialization. The lack of statistical significance in the NHS-Galleri trial's primary endpoint leads to a permanent rejection of broad population-scale reimbursement by the UK NHS and US Medicare, compressing the addressable market to a low-margin or limited self-pay niche. Legal liabilities from class action lawsuits escalate, and the cash burn rate accelerates, forcing dilutive capital raises before 2028.

Base CaseCentral scenario

$72.3850%

Matches the consensus mean

GRAIL maintains steady commercial growth in the self-pay and employer-sponsored markets, with quarterly revenues scaling gradually. The FDA review of the Galleri PMA continues through a standard, potentially prolonged timeline, while reimbursement negotiations with the NHS and CMS remain slow. Legal expenses from the ongoing securities class action lawsuits are manageable, and the company's cash runway remains sufficient to fund operations into 2028.

Bull CaseUpside scenario

$88.0030%

The FDA approves the Galleri PMA application based on PATHFINDER 2 and bridging analyses, unlocking broad commercial adoption. Integration with major EHR platforms like Epic and digital health partnerships (e.g., Hims & Hers) accelerates clinical uptake. Furthermore, longer-term follow-up data from the NHS-Galleri trial eventually demonstrates statistical significance in late-stage cancer reduction, securing favorable coverage from Medicare and international health systems.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage and established leadership in the multi-cancer early detection (MCED) market.
Strong commercial momentum with Galleri test volumes growing 50% YoY to over 56,000 in Q1 2026.
Robust balance sheet with $823.1 million in cash and marketable securities as of March 31, 2026, providing a runway into late 2028.
Strategic commercial integrations, including Epic EHR platform and digital health partnerships.

Key Investment Risks

Failure of the landmark NHS-Galleri trial to meet its primary endpoint of statistically significant Stage III-IV cancer reduction.
Regulatory uncertainty surrounding the active FDA Premarket Approval (PMA) review.
Substantial commercial risk if broad reimbursement from Medicare (CMS) and international health systems is delayed or denied.
Overhanging legal and reputational risks from multiple consolidated securities class action lawsuits alleging misleading disclosures.

Thesis Invalidation Triggers

An outright rejection or major delay of the Galleri PMA by the FDA.
A formal decision by the UK National Health Service to deny national implementation and reimbursement for Galleri.
Adverse rulings or material financial settlements in the ongoing securities class action lawsuits.
A significant acceleration in cash burn that shortens the estimated runway to under 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.